Vinapharma

For international manufacturers

Partnership

Vinapharma is the international partnership arm of MKT Pharma. We source quality medicines from manufacturers worldwide and bring them to Vietnam’s largest distribution network through registered tender pathways and direct hospital relationships.

What we offer

Hospital-direct distribution

Tender wins translate into immediate placement at 1,000+ hospitals and 5,000+ pharmacies, served from 4 GDP-certified warehouses across Vietnam.

DAV dossier expertise

Our regulatory affairs team handles the full registration pathway with the Drug Administration of Vietnam — including tracking the 2024 Pharma Law roll-out and TT12/2025 implementation.

Tender strategy

We position your molecule into the right Vietnam tender Group (1–4) for maximum margin and volume, then defend the listing across hospital cycles.

Local commercial team

100+ staff across 5 offices including a 20-headcount oncology specialty force at Vietnam's top cancer centers (16 reps split 8 South / 6 North / 2 Center, plus product and project management).

Who we look for

We work across three manufacturer tiers, mapped to Vietnam’s tender Group structure.

P1 — Originators / SRA-listed

EU, US, Japan, Korea originators and mid-pharmas with SRA approval (EMA, FDA, PMDA). Vietnam tender Group 1, premium positioning. Typical engagement cycle 3–9 months.

P2 — EU-GMP generics

European, Korean, and India-EU-approved generic manufacturers. Vietnam tender Group 2, volume-and-margin balance. Typical cycle 2–5 months.

P3 — WHO-GMP generics

India, Bangladesh, China WHO-GMP manufacturers. Vietnam tender Group 4, scale and price competitiveness. Typical cycle 1–4 months.

Strategic priorities for new partnerships

Areas where we are actively seeking additional manufacturer partners based on Vietnam tender demand and gaps in our current portfolio:

Afatinib biosimilarsTrastuzumab biosimilarsBevacizumab biosimilarsAdditional Osimertinib partners

Tell us your molecule

We’ll send a personalized 2-page Vietnam Market Entry Brief — tender volume, current originator, regulatory path, and our distribution capability for that therapeutic area.

Request a brief